Contact us: 01476 247 007
How can we help
Pharmacovigilance
National contact person for pharmacovigilance – post Brexit
Pharmacovigilance Standard Operating Procedure Audits
Post Marketing Pharmacovigilance Support
Clinical Trial Pharmacovigilance Support
EU QPPV Provision
Quality & Compliance
Risk Assessment and Management
Signal Detection and Management
Medical Writing
Patient Information
Regulatory
Market Authorisation Holding
Our Partners
External Team
News
Get in touch
✕
Filter by
Categories
Tags
Authors
Show all
All
Brexit Updates
Industry News
NCPP
Patient Information
Pharmacovigilance
Risk Management
All
Aimovig
Brexit updates
British Association for the Study of Headache
CGRP
chronic migraine
Deputy QPPV for Pharmacovigilance
EMA latest guidance
erenumab
EU MA
EU QPPV
EU QPPV for Pharmacovigilance
EU/EEA QPPV
European Marketing Authorisation Holders (MAH)
GCP inspections
Good Clinical Practice inspections
MAH Service
Marketing Authorisation Holders
MHRA latest guidance
MHRA post-transition period information
National Contact Person for Pharmacovigilance (NCPP)
NICE agrees to look again at Novartis’ Aimovig for migraine prevention
Novartis
Periodic Safety Update Reports
pharmacovigilance
Pharmacovigilance (QPPV)
Pharmacovigilance (QPPV) provision post-Brexit
Post-Authorisation Safety Studies-protocols and final study reports
PSMF (pharmacovigilance system master file)
Pure Drug Safety
QPPV (Qualified Person for Pharmacovigilance)
QPPVs based in the UK
remain compliant in the UK
Responsible Person for Eudravigilance in clinical trials
Risk Management Plans
severe migraine
the transition period for Pharmacovigilance and Regulatory
UK and non-UK Individual Case Safety Reports
UK QPPV
All
bone
Liselle Barnsley
There are no posts on the list.
